Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Indegene provides digital-led commercialisation services to global life sciences companies — pharmaceutical, biotech and medical device firms — spanning medical affairs, regulatory writing, pharmacovigilance, marketing/omnichannel content operations, and sales enablement. Listed in May 2024, it combines domain expertise with proprietary technology platforms, with revenue concentrated among large global pharma clients and largely earned in North America and Europe.
It is one of the few listed pure-play life-sciences commercialisation services firms globally.
Indegene Ltd. is a constituent of NIFTY 500, NIFTY SMALLCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Indegene Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 16.72 | 17.15 | 15.19 |
| Book value / share (₹) | 130.51 | 109.21 | 64.37 |
| Return on equity | 12.8% | 15.6% | 24.1% |
| Return on capital employed | 13.9% | 16.4% | 22.2% |
| Operating margin | 14.0% | 16.0% | 16.6% |
| Net margin | 11.4% | 14.3% | 13.0% |
| EBITDA | ₹619 Cr | ₹534 Cr | ₹505 Cr |
| Free cash flow | ₹607 Cr | ₹412 Cr | ₹497 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹403 Cr |
| Debt to equity | 0.00 | 0.00 | 0.28 |
| Interest coverage | 25.5 | 20.6 | 8.7 |
| Current ratio | 2.41 | 4.48 | 2.93 |
| Shares outstanding | 24,05,00,000 | 23,95,00,000 | 22,20,00,000 |
Open the full income statement, balance sheet and cash flow for INDGN →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.